Back to top
more

Labcorp (LH)

(Real Time Quote from BATS)

$214.43 USD

214.43
4,529

+4.94 (2.36%)

Updated Jul 25, 2024 10:14 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Should Value Investors Buy Labcorp (LH) Stock?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Labcorp (LH) is anticipated to drive growth in the first quarter of 2024 through base business expansion, integrating acquisitions and partnerships and advancing in science and technology.

Labcorp's (LH) At-Home Mpox Testing Kit Gets the FDA's EUA Nod

by Zacks Equity Research

Labcorp (LH) receives the FDA's Emergency Use Authorization for the Mpox PCR Test Home Collection Kit.

Myriad Genetics (MYGN) Announces Favorable Research Results

by Zacks Equity Research

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Labcorp's (LH) Strategic Alliances Aid Amid Macroeconomic Woes

by Zacks Equity Research

Labcorp (LH) is investing in innovation and technology that supports diagnostic and drug development testing for various diseases such as cancer and Alzheimer's.

Labcorp (LH) Extends MRD Clinical Research With New Launch

by Zacks Equity Research

Labcorp (LH) Plasma Detect MRD solution advances its leadership in precision oncology across the solid tumor oncology care continuum.

Here's Why Investors Should Retain Labcorp (LH) Stock for Now

by Zacks Equity Research

Investors are optimistic about Labcorp (LH) on the continued strength of Central Labs, which is driving the success of the biopharma segment.

OPKO Health (OPK) to Restructure After Asset Buyout by Labcorp

by Zacks Equity Research

OPKO Health (OPK) expects to re-establish profitability in its clinical laboratory business via its latest efforts to streamline its laboratory services business.

Labcorp (LH) to Boost Clinical Diagnostics With New Deal

by Zacks Equity Research

The recent deal will augment Labcorp's (LH) laboratory services network and expand access to the company's high-quality clinical laboratory services.

Labcorp (LH) Boost Diagnostics Suite With New Biomarker Test

by Zacks Equity Research

Labcorp's (LH) pTau217 test is a pivotal blood biomarker intended to aid in the diagnosis of Alzheimer's disease.

Labcorp (LH) Presents New Research on Precision Diagnostics

by Zacks Equity Research

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Labcorp (LH) Expands Strategic Alliances, Test Sales Fall

by Zacks Equity Research

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.

LH or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

LH vs. COO: Which Stock Is the Better Value Option?

Are Investors Undervaluing Labcorp (LH) Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) Introduces Weight Loss Management Portfolio

by Zacks Equity Research

Labcorp's (LH) Weight Loss Management service includes proven tests from its extensive menu and simplifies the procedure for both physicians and patients.

Here's Why Investors Should Hold Labcorp (LH) Stock for Now

by Zacks Equity Research

Targeted development in high-growth areas and strategic partnerships bode well for Labcorp (LH).

Is Labcorp (LH) Stock Undervalued Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Labcorp (LH) Moves to Buy: Rationale Behind the Upgrade

by Zacks Equity Research

Labcorp (LH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

LH vs. COO: Which Stock Is the Better Value Option?

by Zacks Equity Research

LH vs. COO: Which Stock Is the Better Value Option?

Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics (Revised)

by Zacks Equity Research

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates (Revised)

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Labcorp (LH) Q4 Earnings and Revenues Beat, Margins Fall

by Zacks Equity Research

Strength in Diagnostics Laboratories and Biopharma Laboratory Services businesses contributes to Labcorp's (LH) Q4 performance.

Compared to Estimates, Labcorp (LH) Q4 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Labcorp (LH) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Labcorp (LH) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Labcorp (LH) delivered earnings and revenue surprises of 0.30% and 0.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Labcorp (LH) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Get a deeper insight into the potential performance of Labcorp (LH) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.